📊 IDXX Key Takeaways
Is Idexx Laboratories Inc. /de (IDXX) a Good Investment?
IDEXX demonstrates exceptional operational excellence with 31.6% operating margins, 66% ROE, and accelerating earnings growth (EPS +22.6% vs revenue +10.4%), indicating strong operating leverage in its diagnostics business. The company maintains a conservative 0.28x debt/equity ratio while generating robust $1.1B free cash flow, providing substantial financial flexibility for growth and shareholder returns.
IDEXX delivers durable double-digit growth with industry-leading margins and exceptional returns on capital, translating efficiently into free cash flow. Low leverage and extraordinary interest coverage underscore resilience and capacity to invest through cycles, even with modest on-balance-sheet cash. Continued discipline in working capital will be important as scale increases.
Why Buy Idexx Laboratories Inc. /de Stock? IDXX Key Strengths
- Exceptional profitability: 61.8% gross margin and 31.6% operating margin demonstrate strong pricing power and operational efficiency
- Outstanding capital returns: 66% ROE and 31.6% ROA significantly exceed peer averages, indicating exceptional asset deployment
- Accelerating earnings growth: EPS growing 22.6% YoY vs revenue growth of 10.4% signals strong operational leverage and margin expansion
- Conservative financial structure: 0.28x debt/equity ratio with 171.9x interest coverage provides substantial financial flexibility
- Strong cash generation: $1.1B free cash flow with 24.6% FCF margin demonstrates resilient business model and effective capital conversion
- High profitability with 61.8% gross, 31.6% operating, and 24.6% net margins
- Exceptional ROE (66%) and ROA (31.6%) indicating efficient asset use and strong competitive position
- Robust cash generation and balance sheet strength (FCF margin 24.6%, D/E 0.28x, interest coverage 171.9x)
IDXX Stock Risks: Idexx Laboratories Inc. /de Investment Risks
- Liquidity compression: Current ratio of 1.23x and quick ratio of 0.90x suggest near-term working capital constraints; requires monitoring
- Elevated insider activity: 18 Form 4 filings in 90 days warrants investigation into transaction nature and motivations
- Execution risk: Sustaining 31.6% operating margins amid inflationary pressures and competitive dynamics in diagnostics market
- Tight liquidity profile (current 1.23x, quick 0.90x) and relatively low cash balance
- Potential growth normalization after strong comps; operating leverage could reverse if growth slows
- Regulatory/quality or product-cycle risks inherent to diagnostics that could affect demand and margins
Key Metrics to Watch
- Gross margin trend - sustainability amid cost inflation and competitive pressures
- Organic revenue growth rate - distinguishing organic expansion from acquisition contributions
- Free cash flow conversion - maintenance of 24.6% FCF margin relative to net income
- Current and quick ratio trends - liquidity position monitoring
- Debt levels and leverage ratios - capital structure evolution
- Organic revenue growth (YoY)
- Free cash flow margin
Idexx Laboratories Inc. /de (IDXX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 24.6% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments.
IDXX Profit Margin, ROE & Profitability Analysis
IDXX vs Healthcare Sector: How Idexx Laboratories Inc. /de Compares
How Idexx Laboratories Inc. /de compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Idexx Laboratories Inc. /de Stock Overvalued? IDXX Valuation Analysis 2026
Based on fundamental analysis, Idexx Laboratories Inc. /de appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Idexx Laboratories Inc. /de Balance Sheet: IDXX Debt, Cash & Liquidity
IDXX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Idexx Laboratories Inc. /de's revenue has grown significantly by 34% over the 5-year period, indicating strong business expansion. The most recent EPS of $10.06 reflects profitable operations.
IDXX Revenue Growth, EPS Growth & YoY Performance
IDXX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $975.5M | $203.3M | $2.80 |
| Q2 2025 | $1.0B | $203.3M | $2.44 |
| Q1 2025 | $964.1M | $235.6M | $2.81 |
| Q3 2024 | $915.5M | $203.3M | $2.53 |
| Q2 2024 | $943.6M | $203.3M | $2.44 |
| Q1 2024 | $900.2M | $214.1M | $2.55 |
| Q3 2023 | $841.7M | $132.0M | $2.15 |
| Q2 2023 | $860.5M | $132.0M | $1.56 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Idexx Laboratories Inc. /de Dividends, Buybacks & Capital Allocation
IDXX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Idexx Laboratories Inc. /de (CIK: 0000874716)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IDXX
What is the AI rating for IDXX?
Idexx Laboratories Inc. /de (IDXX) has a Combined AI Rating of STRONG BUY from Claude (STRONG BUY) and ChatGPT (STRONG BUY) with 87% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IDXX's key strengths?
Claude: Exceptional profitability: 61.8% gross margin and 31.6% operating margin demonstrate strong pricing power and operational efficiency. Outstanding capital returns: 66% ROE and 31.6% ROA significantly exceed peer averages, indicating exceptional asset deployment. ChatGPT: High profitability with 61.8% gross, 31.6% operating, and 24.6% net margins. Exceptional ROE (66%) and ROA (31.6%) indicating efficient asset use and strong competitive position.
What are the risks of investing in IDXX?
Claude: Liquidity compression: Current ratio of 1.23x and quick ratio of 0.90x suggest near-term working capital constraints; requires monitoring. Elevated insider activity: 18 Form 4 filings in 90 days warrants investigation into transaction nature and motivations. ChatGPT: Tight liquidity profile (current 1.23x, quick 0.90x) and relatively low cash balance. Potential growth normalization after strong comps; operating leverage could reverse if growth slows.
What is IDXX's revenue and growth?
Idexx Laboratories Inc. /de reported revenue of $4.3B.
Does IDXX pay dividends?
Idexx Laboratories Inc. /de does not currently pay dividends.
Where can I find IDXX SEC filings?
Official SEC filings for Idexx Laboratories Inc. /de (CIK: 0000874716) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IDXX's EPS?
Idexx Laboratories Inc. /de has a diluted EPS of $13.08.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IDXX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Idexx Laboratories Inc. /de has a STRONG BUY rating with 87% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is IDXX stock overvalued or undervalued?
Valuation metrics for IDXX: ROE of 66.0% (sector avg: 15%), net margin of 24.6% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy IDXX stock in 2026?
Our dual AI analysis gives Idexx Laboratories Inc. /de a combined STRONG BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is IDXX's free cash flow?
Idexx Laboratories Inc. /de's operating cash flow is $1.2B, with capital expenditures of $124.7M. FCF margin is 24.6%.
How does IDXX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 24.6% (avg: 12%), ROE 66.0% (avg: 15%), current ratio 1.23 (avg: 2).
Why is IDXX's return on equity (ROE) so high?
Idexx Laboratories Inc. /de has a return on equity of 66.0%, significantly above the Healthcare sector average of 15%. A high ROE indicates the company is efficient at generating profits from shareholder equity. This is supported by a 24.6% net margin.